In ovarian mucinous tumors, cyclin dependent kinase inhibitor 2A (CDKN2A) and KRAS mutations represent the most common genetic alterations in both ovarian mucinous adenocarcinoma and their precursor lesions. This evidence concerns the gene CDKN2A and ovarian mucinous adenocarcinoma.